Cryptococcus neoformans is a significant global fungal pathogen and remains a life-threatening clinical issue in immune-compromised hosts. Creative Biolabs has successfully established a custom antifungal drug discovery platform with multiple high-end technologies. We are committed to assisting you in your antifungal drug development against cryptococcus neoformans.
Introduction of Cryptococcus Neoformans
Cryptococcus neoformans (C. neoformans) is a major opportunistic fungal pathogen that is usually found in the environment, in particular soils and pigeon excreta. C. neoformans causes fatal meningoencephalitis in immunocompromised hosts, including those with AIDS, as well as transplant recipients and cancer patients receiving conditioning regimens or chemotherapy, respectively. Worldwide, C. neoformans causes an estimated 1 million new infections and over 625,000 deaths annually and continues to cause a significant infectious burden in both AIDS and non-AIDS patients. C. neoformans also remains the third most common invasive fungal infection among organ transplant recipients. Defense against C. neoformans largely depends on innate response and Th1 polarization.
Fig.1 Cryptococcus Neoformans. (Recio, 2018)
Infection and Treatment of Cryptococcus Neoformans
C. neoformans is a pathogenic fungus found worldwide, which is characterized by the presence of an anti-phagocytic capsule. Clinical cases of C.neoformans infection have become increasingly more prevalent over the past several decades, and patient prognosis is highly dependent on the ability of hosts to mount an effective immune response. In immunocompetent individuals, pulmonary infection by C. neoformans is generally asymptomatic. However, the organism can cause life-threatening complications in immunocompromised states, such as in AIDS and in patients undergoing immune-suppressive therapy. In the later stages of AIDS, the uncontrolled dispersal of C. neoformans in the lungs can cause severe and highly recurrent meningoencephalitis, which affects approximately 4-8% of AIDS patients.
Despite progress in the development of novel antifungal therapies, these treatments have not completely eradicated C. neoformans infection. The difficulty in eradicating this organism lies in the intrinsic properties of its capsule, which can possibly explain the reasons behind its persistence and recurrence.
With the help of our well-established technologies and skillful scientific team, Creative Biolabs is capable of providing one-stop antifungal drug discovery service, including target identification and validation, Hit identification, Hit to lead, Lead optimization, and IND enabling to meet the novel drug discovery goals.
Creative Biolabs offers valuable suggestions and reliable services for our worldwide clients to support your study of C. neoformans. We are pleased to provide custom antifungal drug discovery services to facilitate our clients’ research and project development. Please do not hesitate to contact us for more information.
Reference
For Research Use Only.
